MiMedx Group (MDXG), a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare.
MDXG processes the human placental tissue utilizing its proprietary PURION Process to produce allografts. The company's proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. Its biomaterial platform technologies include AmnioFix and EpiFix that are tissue technologies processed from human amniotic membrane derived from donated placental tissue for homologous applications; OrthoFlo, an amniotic fluid-derived allograft for homologous applications; Physio, a bone grafting material comprising 100% bone tissue with no added carrier; and CollaFix, a technology platform derived from collagen fiber technology designed to mimic the natural composition, structure, and mechanical properties of musculoskeletal tissues to augment their repair.
MDXG also offers EpiCord, an umbilical cord allograft that provides a connective tissue matrix to replace or supplement damaged or inadequate integumental tissue; AmnioCord, an umbilical cord allograft that offers a protective environment for the healing process; and AmnioFill, a cellular tissue matrix allograft that enhances healing.
Its products have applications in the areas of wound care, burns, surgery, orthopedics, spine, sports medicine, ophthalmology, and dentistry.
MiMedx Group, Inc. is headquartered in Marietta, Georgia.
March 4, 2021
RegMed Investors’ (RMi) pre-open: slim pickings
35 companies, 1 interpreter!
Insight, foresight and recommendation
MiMedx Group (MDXG) – opened 2018 at $12.98, trooped in February to $17.13 and dropped to $8.75 with a slight rebound to $9.00 on 2/21 after 2/20's shares were halted in premarket trade on news that the company is delaying the release of Q4/17 and full-year ‘17 earnings to conduct an accounting review. The audit committee has hired legal and accounting advisers to conduct an internal investigation of allegations relating to sales and distribution practices..Executives are reviewing the accounting treatment of certain distributor contracts, among other items. "The company believes, based on information available to date, that the outcome of such investigation should not have a material impact on revenue guidance for 2018," said a statement. The company had about $33 million in cash and cash equivalents at year-end and has no debt. Shares have gained 75% in the last 12 months through Friday. Amid buzz is a short seller’s visit by the FBI, MDXG has been involved in a nasty relationship with short sellers that recently took a turn for the worse. Now, MDXG’s internal investigation is delaying the release of its financial results, including its annual statement that would detail last year’s performance - a serious hiccup yet still will be a performer after the clean-upbuy
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at firstname.lastname@example.org.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors